To evaluate the inhibitory efficacy of GPR56-PIPs on GPR56 expression, EVI1high AML cell lines (UCSD/AML1 and Kasumi-3) were treated with 1 and 5 μM GPR56-PIPs (PIP/56-1, PIP/56-1/m, or PIP/56-2) and PIP/AP2, which targets the binding site of the AP2 transcription factor22. Here, ADGRG1 is linked to acute myeloid leukemia.